Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
NCT ID: NCT00150813
Last Updated: 2018-11-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
66 participants
INTERVENTIONAL
2005-08-10
2007-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
NCT00150787
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
NCT00150735
Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
NCT00291655
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
NCT00150748
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
NCT01506882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levetiracetam
Subjects received open-label Levetiracetam.
Levetiracetam
Pharmaceutical form: oral tablets Route of administration: Oral use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levetiracetam
Pharmaceutical form: oral tablets Route of administration: Oral use
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin),or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures
* Subjects having participated in the previous double-blind monotherapy trial (N01061 \[NCT00150735\] or N01093 \[NCT00150787\]).
* Male/female subjects (\>= 16 years).
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beroun, , Czechia
Brno, , Czechia
České Budějovice, , Czechia
Prague, , Czechia
Rychnov nad Kněžnou, , Czechia
Budapest, , Hungary
Debrecen, , Hungary
Pécs, , Hungary
Szeged, , Hungary
Bialystok, , Poland
Gdansk, , Poland
Katowice, , Poland
Lodz, , Poland
Lublin, , Poland
Szczecin, , Poland
Warsaw, , Poland
Gothenburg, , Sweden
Helsingborg, , Sweden
Huddinge, , Sweden
Karlstad, , Sweden
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N01127
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.